Abstract
The emergence of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) reawakened the need to rapidly understand the molecular etiologies, pandemic potential, and prospective treatments of infectious agents. The lack of existing data on SARS-CoV-2 hampered early attempts to treat severe forms of coronavirus disease-2019 (COVID-19) during the pandemic. This study coupled existing transcriptomic data from severe acute respiratory syndrome-related coronavirus 1 (SARS-CoV-1) lung infection animal studies with crowdsourcing statistical approaches to derive temporal meta-signatures of host responses during early viral accumulation and subsequent clearance stages. Unsupervised and supervised machine learning approaches identified top dysregulated genes and potential biomarkers (e.g. CXCL10, BEX2, and ADM). Temporal meta-signatures revealed distinct gene expression programs with biological implications to a series of host responses underlying sustained Cxcl10 expression and Stat signaling. Cell cycle switched from G1/G0 phase genes, early in infection, to a G2/M gene signature during late infection that correlated with the enrichment of DNA damage response and repair genes. The SARS-CoV-1 meta-signatures were shown to closely emulate human SARS-CoV-2 host responses from emerging RNAseq, single cell, and proteomics data with early monocyte-macrophage activation followed by lymphocyte proliferation. The circulatory hormone adrenomedullin was observed as maximally elevated in elderly patients who died from COVID-19. Stage-specific correlations to compounds with potential to treat COVID-19 and future coronavirus infections were in part validated by a subset of twenty-four that are in clinical trials to treat COVID-19. This study represents a roadmap to leverage existing data in the public domain to derive novel molecular and biological insights and potential treatments to emerging human pathogens.
Keywords: host transcriptomic response, host proteomic response, machine learning, adrenomedullin, coronavirus infection
Introduction
The respiratory disease known as coronavirus disease-2019 (COVID-19) is caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), a species individuum within the Betacoronavirus genus and Coronaviridae family [1]. Since emerging as a deadly human pathogen in December 2019, it has triggered a devastating global pandemic that may pervade humanity for years to come [2]. While SARS-CoV-2 is the causative agent of COVID-19, it is just one of many respiratory viruses that arise and reemerge regularly. Vaccination has been shown to mitigate severe responses to SARS-CoV-2, but as the best therapeutic option to date, it does not always prevent infection or hospitalization [3–5]. As evident in this pandemic, there is need for more therapies that can act before new vaccines are developed to emerging pathogens, treat unvaccinated people and those infected by vaccine-resistant variants [6].
Many aspects of the cellular and molecular biology of the host infection response to SARS-CoV-2 are not well understood given its recent presumed zoonotic emergence as a human pathogen. The SARS-CoV-2 single positive-strand RNA genome shares a 79% nucleotide identity to severe acute respiratory syndrome-related coronavirus 1 (SARS-CoV-1), which caused a much smaller pandemic in 2002 [7–10]. Both viruses appear to have originated in bats and bind the Angiotensin Receptor 2 on host cells mainly via the viral spike protein to initiate cellular entry [11]. The Middle East respiratory syndrome-related coronavirus (MERS-CoV) caused international outbreaks in 2012 and 2015 [8, 12]; it differs from SARS-CoV viruses by binding to the dipeptidyl peptidase 4 receptor for cell entry [13, 14]. A more complete understanding of coronavirus host infection mechanisms is necessary in preparation for combatting future outbreaks.
Coronavirus genomes are unusually large compared to other viruses [15]. The 26 000 to 32 000 nucleotide genomes contain a varying number of open reading frames that encode 20 or more proteins, including a set of highly conserved replicase enzymes and the nucleocapsid, spike, membrane, and envelope structural proteins in SARS-CoV-1, SARS-CoV-2, and MERS-CoV [9, 13, 16]. Less conserved accessory proteins localize broadly to the cell surface, cytoplasm, various organelles, and the nucleus of host-infected cells [17]. The breadth of functional effects is impressive. A deeper understanding of common viral-induced adverse cellular events and the temporal order of host molecular and pathway level response could provide opportunities for therapeutic intervention irrespective of infecting Betacoronavirus type [18].
Meta-analysis workflows integrate observations across independent studies [19]. More robust insights can be gained compared to single studies because each study has inherent variability that can be minimized when assessing a set of related studies. Variability embedded in medical research can originate, for example, in the methods of sample collection, experimental platform (e.g. microarrays vs. sequencing), or in the pipeline of algorithms used to process raw data. Meta-analysis can be done by merging datasets together or by using ensemble methods that utilize “wisdom of crowds” approaches [20, 21]. The latter crowdsourcing approach has distinctive advantages as overall error in the “crowd” or collection of datasets can be minimized when factoring each individual study error. By using the same comparison criteria (e.g. coronavirus-infected lung tissue vs. mock-infected lung tissue), crowdsourcing results can faithfully build observational consensus and reliability.
The current study applied a novel “wisdom of crowds” technique to generate temporal gene expression meta-signatures from 15 independent RNA expression studies comprising 74 SARS-CoV-1 lung-infected vs. mock-infected comparisons in mouse at 0.5, 1, 2, 4, and 7 days post-infection. The meta-signatures provide a robust molecular representation of disease progression that has been supported by emerging studies on SAR-CoV-2. Furthermore, functionally inverse correlations to mechanistically distinct compound treatments provide a means to anticipate potential benefit of single or combination treatments.
The overarching goals of this study are to: (i) present a general guide to crowdsourcing publicly available transcriptomic data; (ii) provide a resource of data and metadata on SARS-CoV infection; (iii) identify drugs with potential to treat specific biomarker-based stages of disease; and (iv) derive actionable insights of SARS-COV-2 host response in humans. The authors invite engagement of the coronavirus research community by providing data, tools, and resources to help advance research on coronavirus infectivity. An interactive portal is available as a public resource (http://18.222.95.219:8047).
Methods
Illumina’s BaseSpace™ Correlation Engine [22] (BSCE, previously known as NextBio) was used to facilitate the aggregation and mining of coronavirus host infection transcriptome data for two main reasons. BSCE contains over 21 500 omic-scale Curated Studies with over 132 000 experimental comparison results comprising significance filtered gene lists with fold change and P-values (hereafter called biosets). Consistent curation practices ensure the inclusion of high quality datasets for analysis and improve the resulting interpretations. Curated Studies in BSCE are processed in standard, platform-specific pipelines to generate gene sets and measures. For each study, available Test group vs. Control group results plus experimental metadata are generated. Second, BSCE has robust data-driven correlation, aggregation, and machine learning applications to exploit the consistent processing and curation of omic-scale studies derived from international public repositories, including US-NCBI’s Gene Expression Omnibus [23] and the Short Read Archive [24], EMBL-EBI’s Array Express [25], US-NIEHS’s NTP Chemical Effects in Biological Systems [26], and Japan’s Toxicogenomics Project-Genomics Assisted Toxicity Evaluation System [27].
Systematic review of omic-scale studies and experimental designs
A search of BSCE identified 44 Curated Studies with a total of 447 biosets querying the term “Coronavirus.” The biosets covered a wide range of experimental designs across an array of viral species, viral individuum variants, viral dose, post-infection duration, host organism, host tissue, host sex, host age, gene knockout models, cell line models, compound treatments, and technology platforms. Study and experimental bioset details were hand curated from BSCE, the GEO entry, and primary articles. Only SARS-CoV-1 had broadly representative temporal data to support a crowdsourcing approach. Other coronavirus species like MERS-CoV and human alphacoronavirus while present in BSCE did not have sufficient temporal data. At the time of writing, BSCE did not have SARS-CoV-2 Curated Studies and those discussed were imported from data provided in primary publications.
RNA expression analysis and bioset generation
Threshold filters between test (e.g. virus infection) and control (e.g. mock infection) conditions were applied to log2 scale RNA expression data. Genes with both mean normalized test and control intensities less than the 20th percentile of the combined normalized signal intensities were removed. A parametric Welch t-test, where variances are not assumed equal, is calculated and genes with a P >.05 were removed. An additional filter removes genes with non-log2 absolute fold change <1.2 to generate the final list of differentially expressed genes with directional fold change, rank, P-value and a normalized score that corrects for platform differences and significant gene count resulting in a bioset. The parametrically determined gene list is set to non-parametric ranks by assigning the gene with the highest absolute fold change the highest rank of 1 and genes descending by absolute fold change are numbered down the ordinal ranks. Bioset–Bioset correlations are done based on the ranks using the Running Fisher algorithm [22]. BSCE calculates normalized, bioset-specific gene scores that consider the absolute fold change rank, the number of genes passing threshold filters, and the number of genes measured by the platform on a 100-to-0 scale. A positive or negative sign was appended to gene scores based on the fold change direction to generate values ranging from −100 to +100, here forth called directional gene score(s).
Initial RNA expression analysis of SARS-CoV-1 lung-infected vs. mock-infected control used biosets from four mammalian species and nine beta-coronavirus variants, encompassing 19 Curated Studies with a total of 97 biosets [Mus musculus—mouse (n = 85), Macaca fascicularis—cynomolgus macaques (n = 5), Mustela putorius furo—ferret (n = 5), and in Homo sapiens—human cells (n = 2)]. Biosets covered 48 early-, 42 mid-, and 7 late-stage infection results [0.5, 1, 2, 3, 4, 5, 7, 14, 21, and 28 days post-infection (dpi)]. Beta-coronavirus variants included SARS-CoV-MA15, SARS-CoV-MA15e, SARS-CoV-MA15g, SARS-CoV-TOR-2, SARS-CoV-GZ02, SARS-CoV-HC-SZ-6103, SARS-CoV-ic, SARS-CoV-Urbani, and SARS-CoV-2 USA-WA1/2020 (NR-52281). A lethal SARS-CoV-MA15 virus was created by serial passage of the natural SARS-CoV-Urbani variant in the lungs of mice [28]. Technology Platforms included [Agilent-014868 Whole Mouse Genome Microarray 4x44K G4122F, Affymetrix Mouse Genome 430 2.0, Affymetrix Canine Genome 2.0 Array, Array Affymetrix Rhesus Macaque Genome Array, Illumina NextSeq 500]. We filtered the time course based on the number of biosets available per dpi; those with less than three biosets were excluded to minimize skewing from an overreaching but underrepresented variable set. This left 74 SARS-CoV-1 lung-infected vs. mock-infected biosets in mouse at 0.5, 1, 2, 4, and 7 dpi comprised of 299 experimental and 239 control animals as the focus for the current study. Metadata and a gene expression matrix are in Supplementary Table 1.
Generation and analysis of temporal Meta-Signatures
The 74 biosets spanned (i) five post-infection time points, (ii) three host age groups, (iii) three host strains, (iv) five viral variants, and (v) four magnitudes of viral dose. Age groups were divided into young mice (≤10 weeks), adult (20–23 weeks), and aged (52 weeks). To the best of our knowledge all were female. M. musculus strains included BALB/c, 129/S6/SvEv, and C57BL/6NJ. The most commonly used MA15 viral variant induces more severe reactions in mice than MA15g, MA15e, or the ic (infectious clone) and wildtype TOR-2 variants [28, 29]. Intranasal infection dose levels included 100, 1000, 10 000, 22 000, and 100 000 viral plaque forming units (pfu). As with humans afflicted with SARS-CoV-2, younger hosts appear less susceptible to the effects of the SARS-CoV-MA15 virus than aged mice [30]. Severity across age groups was also measured by the number of genes differentially expressed as viral inoculation dose increased over four magnitudes.
The BSCE meta-analysis application was used to aggregate biosets and generate five time-specific lists of significant genes. Meta-analysis was run separately in sets for six biosets at 0.5 dpi, 15 biosets at 1 dpi, 19 biosets at 2 dpi, 19 biosets at 4 dpi, and 15 biosets at 7 dpi. The average of the directional gene score values was taken for each gene in the set, here forth called temporal gene score(s), to generate five temporal multi-gene meta-signatures that were aligned into a matrix to form 10 564 gene-specific time vectors following host response to SARS-CoV-1 infection in mouse lungs (Supplementary Table 2). The Venn diagram was generated using the Gent University Bioinformatics and Evolutionary Genomics application at http://bioinformatics.psb.ugent.be/webtools/Venn/. Profile charts were generated using JMP® Pro 15.0 (SAS Institute Inc., Cary, NC).
The BSCE Pathway Enrichment application was used to correlate and rank the temporal meta-signatures to functional biogroup lists derived from Gene Ontology (GO) [31, 32]. Biogroup concepts with a minimum of 10 and a maximum of 750 genes were used, thereby eliminating minor concepts and those with little specificity.
Network Analysis was performed using STRING, Protein–Protein Interaction Networks, and Functional Enrichment Analysis at https://string-db.org [33] and Pathway Studio (Elsevier B.V., Amsterdam, The Netherlands). Other gene function analyses were performed using the WEB-based GEne SeT AnaLysis Toolkit software (http://www.webgestalt.org/) [34, 35].
Unsupervised and supervised machine learning analyses
Principal Component Analysis (PCA) of the 74 biosets used Partek Genomics Suite Version 7.21.1119 with PC product values, ellipsoids were graphically rendered at two standard deviations from centroid points. Partek was also used for F-value generation (between group variance/within group variance) to provide measures for experimental sources of variation. The F Distribution Calculator at https://www.statology.org/f-distribution-calculator/ was used to derive P-values using experimental variable degrees of freedom and the F-values.
Agglomerative hierarchical clustering for the 74 biosets and for the five temporal meta-signatures was performed separately by generating a static heatmap using the native R heatmap function “heatmap.2,” which orders features based on Euclidian distance and nearest neighbors agglomeration, no additional normalization was performed, and no parameters adjusted. Row and column dendrograms were isolated from the static heatmap and applied to third party heatmap packages “heatmaply” [36] and “InteractiveComplexHeatmap” [37] to generate interactive heatmaps.
For supervised machine learning, a binary elastic-net logistic regression combined with bootstrapping was applied to derive predictive models and robust coefficients of the genes in making temporal predictions [38, 39]. Given observations of distinctive early vs. late activities, samples were grouped as either early [0.5, 1, 2 dpi] or late [4, 7 dpi] to derive a small set of genes that could predict the stage of SARS-CoV-1 infection. Each bootstrap split the data into different training and testing sets with a ratio 4:1 using the “train_test_split” function from sklearn [40] with “stratify = y” and a random seed generated using “randrange” function. One hundred different splits were generated by repeatedly calling “randrange” function in “train_test_split” and any duplicated splits were programmatically removed. For each split, a combination of 3-fold cross-validation and hyperparameters search was performed using the “GridSearchCV” function with “cv = 3” from sklearn on the training set. The two hyperparameters, “C” and “l1_ratio” were the targets of the grid search. The “C” parameter is the inverse of lambda, which controls the overall strength of the regulation term in elastic net, and was set to 1e-4, 1e-3, 1e-2, 1e-1, 1, and 10. The “l1_ratio” controls the ratio between L1 and L2 regulation terms, which was 0.2, 0.4, 0.6, 0.8, and 1. The combination of these two hyperparameters with the lowest cross-validation error was selected and used to derive the coefficient for each gene in the model to predict the early or late stage for each sample in the validation and test sets. The validation accuracy was reported as training accuracy and the test accuracy was calculated by using “accuracy_score” function from sklearn by using the best model on testing set. The coefficients of the genes from these 100 bootstraps were summarized and only genes with at least 90 of 100 bootstraps with a non-zero weight were reported in the final list with the average coefficient and standard deviation.
Correlations to compound treatments, gene perturbations, and diseases
The five temporal meta-signatures were imported into BSCE as biosets and queried in the BSCE Pharmaco, Knockout, Knockdown, and Disease Atlas applications. Bioset queries made against the entire repository yield a Bioset–Bioset correlation rank ordered list. BSCE biosets are tagged with concept terms that capture sample and experimental details, like compound treatments, genetic perturbations, and phenotypes. A machine learning categorization process assesses the rank of correlations to the tagged concept term results into Pharmaco, Knockdown, and Disease Atlases using relevant tag types and strength of contributing bioset correlations (BSCE Supplementary Text). The BSCE Pharmaco Atlas application was used to categorize, and rank compounds based on meta-signature correlations to all “treatment vs. control” biosets in the system (4804 compounds in 53 723 biosets from 6852 studies). The BSCE Knockdown Atlas application was used to categorize, and rank genes based on meta-signature correlations to all “gene perturbation vs. control” biosets in the system (5341 genes perturbed in 37 838 biosets from 10 287 Curated Studies). The BSCE Disease Atlas application was used to categorize, and rank disease phenotypes based on queries with (i) the genes Cxcl10 and Bex2 and (ii) temporal meta-signature correlations to all “disease phenotype vs. normal” biosets in the system (5309 phenotypes in 68 697 biosets from 12 929 Curated Studies).
Compound scores, and separately gene knockout scores, were scaled from −100 to +100 for each meta-signature timepoint and aggregated into a matrix of correlative perturbation time vectors over the course of SARS-CoV-1 infection. Compounds known to be in clinical trials were derived from https://ghddi-ailab.github.io/Targeting2019-nCoV/clinical.
Correlations to human COVID-19 single cell RNAseq and plasma proteomic studies
Single cell RNAseq data were obtained from references [41–44]. Tables from each of the articles were downloaded and divided into individual cell-type-specific bioset files and imported into BSCE as Curated Studies for bioset–bioset correlations to temporal meta-signatures and gene clusters.
Plasma proteomic data generated from 384 patients presenting with acute respiratory distress in a hospital Emergency Department, of whom 306 were COVID-19 positive (blood sampled on days 0, 3, 7, and 28) and 78 non-COVID-19 controls (sampled only on day 0), were downloaded from https://www.olink.com/application/mgh-covid-19-study [45]. Disease severity was divided into five categories of increasing progression: (i) not hospitalized, (ii) hospitalized, no supplemental oxygen required, (iii) hospitalized, supplemental oxygen required, (iv) hospitalized, intubated, ventilated, and survived to 28 days, and (v) death within 28 days. WHOmax was captured as the patient’s most severe category over time.
Interactive portal
The 74 Bioset and the 5 Temporal Meta-Signature results were collaboratively explored using Illumina Connected Analytics (https://www.illumina.com/products/by-type/informatics-products/connected-analytics.html) and then developed into an interactive portal using Dash by Plotly (http://conference.scipy.org/proceedings/scipy2019/shammamah_hossain.html) with the following features: (i) table view with gene search and meta-signature gene profile plots, (ii) PCA, and (iii) agglomerative clustering heatmaps. Access is available at http://18.222.95.219:8047. While Dash by Plotly supports most common computer and browser configurations, there may be cases where this portal may not perform satisfactorily. Accessing the portal through a Virtual Private Network can also interfere with connecting to the portal. The data and code are also available at GitHub (https://github.com/Mark-A-Taylor/Coronavirus_Portal.git/).
Results
The development of temporal meta-signatures of host coronavirus infection and the process used to derive biological interpretation is presented in Fig. 1. The approach followed eight main steps: (i) an assessment of available coronavirus Curated Studies in BSCE, (ii) aggregating biosets of interest, (iii) applying the BSCE Meta-Analysis application to provide normalized gene scores, (iv) creation of meta-signatures, (v) functional enrichment, (vi) network analysis, (vii) ranking of genes knocked out based on the strength of correlations to gene perturbation, and (viii) ranking of compounds based on the strength of correlations to compound treatment.
Figure 1.
Workflow for coronavirus host infection biomarker discovery. The schematic diagram outlines the process to derive and analyze an aggregate gene signature from an unbiased accounting of all coronavirus RNA expression data available from Gene Expression Omnibus and in BaseSpace™ Correlation Engine (BSCE) Curated Studies. Dpi, days post-infection.
Analysis of 74 SARS-CoV-1 lung infection biosets
To combine data from different studies, datasets were normalized using fold-change-based gene score values on a scale of −100 to +100 (directional gene score) (see section “Methods” and Supplementary Table 1). Figure 2A shows an example of the distributions of gene expression values from two biosets at 2 dpi before and after normalization. One bioset is from lungs of young mice infected with the less severe TOR-2 coronavirus variant vs. mock infected controls run on an Affymetrix microarray platform; the other is from lungs of aged mice infected with a lethal MA15 coronavirus variant- vs. mock-infected controls run on an Agilent microarray platform. The graphs show the normalized datapoints have a better linear fit than unnormalized fold change values (R2 of 0.683 vs. 0.507, respectively), are more evenly distributed and better suited for ensemble meta-analysis.
Figure 2.
Coronavirus bioset normalization and attribute distribution. (A) Graphs show the decisive effects of directional gene score normalization vs. fold change values for two biosets compared across different model systems and technologies at 2 dpi. The top panel shows box plots with the distribution of the directional gene scores vs. fold changes. Rank-based scoring of fold change data converts biosets into a uniform −100 to +100 directional gene score list that accounts for a platforms’ number of measured genes and the feature size of each bioset. (B) Bioset count breakdown by age group, dpi, and viral variant. (C) Bioset count breakdown by age group, dpi, viral variant, and viral dose. (D) Differentially expressed gene count breakdown by dpi, viral variant, and viral dose. ±SE is shown where applicable. (F) Sources of variation plot across experimental factors.
Experimental variables spanning bioset count, host age group, viral dose, and viral variants across dpi show a diversified sample set to mine for distinctive characteristics (Fig. 2B and C). The 74 biosets spanned (i) five post-infection times, (ii) three host age groups, (iii) five SARS-CoV-1 viral variants, and (iv) four magnitudes of viral doses. Post-infection times were 0.5 dpi (n = 6), 1 dpi (n = 15), 2 dpi (n = 19), 4 dpi (n = 19), and 7 dpi (n = 15). Age groups were divided into young mice (10 weeks, n = 28), adult (20–23 weeks, n = 37), and aged (52 weeks, n = 9). The most commonly used MA15 viral variant (n = 54) induced more severe reactions in mice than MA15g (n = 7) and MA15e (n = 7) or ic (n = 4) and TOR-2 (n = 2). Intranasal infection dose levels included 100 (n = 4), 1000 (n = 4), 10 000 (n = 15), 22 000 (n = 2), and 100 000 (n = 49) viral pfu. As a measure of host response, the number of significant differentially expressed genes was affected by viral variant, pfu, and age of mice (Fig. 2D and Supplementary Table 1). By these measures, variant severity was ordered in escalation with MA15 > MA15g > MA15e > TOR-2 > ic. Two-way agglomerative hierarchical clustering of the 74 biosets showed groupings of common gene activities and sample type dispersion of host age, dpi, viral variant, and viral dose (Supplementary Fig. 1). PCAs were run to understand the influence of experimental factors, only dpi showed good separation of samples with a rotational trajectory of samples from the origin to 0.5 dpi to 1 dpi to 2 dpi and circling back toward the origin at 4 dpi to 7 dpi (Fig. 2E, see portal). Figure 2F shows relative sources of variation across experimental factors, dpi was the only experimental variable to pass significance (P = .014).
Discovery of coordinated host response gene programs following coronavirus infection
Guided by the analysis of the 74 biosets presented above, the directional gene scores derived from the biosets were aggregated by dpi and averaged within each timepoint thereby generating 10 564 gene vectors comprised of five temporal gene scores providing magnitude and direction (Supplementary Table 2). The Venn diagram in Fig. 3A shows 410 genes common to all timepoints, whereas hundreds of genes were specific for each dpi. The highest overlap of unique genes in paired timepoints occurred between 4 dpi vs. 7 dpi (753 genes) and 1 dpi vs. 2 dpi (633 genes). The least unique overlap occurred between 0.5 dpi vs. 7 dpi (170 genes) followed by 0.5 dpi vs. 1 dpi (244 genes) and 2 dpi vs. 4 dpi (290 genes). These results, supported by the PCA in Fig. 1E, indicate a clear transition between early (0.5–2 dpi) vs. late (4–7 dpi) infection, consistent with the early accumulation and subsequent clearance of SARS-CoV-1 or SARS-CoV-2 in mouse models [46, 47], as represented in Fig. 3A, left graph.
Figure 3.
Temporal meta-signature profiles revealed distinct gene programs during coronavirus infection. (A) The Venn diagram shows the overlap of genes based on the temporal gene scores across the 5 dpi time points. The graph on the right shows an idealized plot of the coronavirus load vs. dpi from published SARS-CoV-1 and SARS-CoV-2 mouse models [46, 47]. (B) Two-way agglomerative hierarchical clustering of meta-signature genes was performed and revealed distinct gene expression patterns (I–IV), including genes that were highly up-regulated (e.g., Cxcl10) or down-regulated (e.g. Bex2) following infection. (C) The upper panel shows the temporal gene score line plots for Cxcl genes and the cognate receptor across dpi, whereas the lower panel shows the underlying directional gene scores by viral dose. (D) The upper panel shows the Bex2 directional gene scores by viral dose across dpi, whereas the lower panel shows the Bex2 directional gene scores by viral variant and age. Where adequate replicates were available, mean values ± SE are shown. (E) The 15 genes in the Bex2 highly down-regulated cluster (pattern IV in panel (B)) were used to generate a STRING protein-protein network based on published data (see section “Methods”).
Agglomerative hierarchical clustering revealed temporal meta-signature gene profiles that may constitute coordinated intercellular gene programs. These profiles are illustrated by the four patterns highlighted in Fig. 3B: (i) genes that are highly up-regulated at 1–2 dpi, (ii) genes highly up-regulated at 4–7 dpi, (iii) genes highly up-regulated through most timepoints, and (iv) genes highly down-regulated through most timepoints. The highest-ranking up-regulated gene across all dpi (in pattern iii) was Cxcl10 (C-X-C motif chemokine ligand 10) (Supplementary Table 2). The immunoregulatory role CXCL10 has in exacerbating cytokine storm syndromes including COVID-19 has been commonly recognized [48]. The local uptake of interferon gamma by alveolar macrophages triggers release of CXCL10 that subsequently attracts a variety of lymphocytes to migrate toward and infiltrate disease tissue [49, 50]. BSCE produced 6059 Curated Studies containing 19 358 Biosets, where Cxcl10 dysregulation was observed across a wide range of experimental and biological designs (Supplementary Table 3). Analysis of Cxcl10 in the BSCE Disease Atlas revealed severe acute respiratory syndrome (SARS) as the most highly correlated phenotype. Cxcl10 was also up-regulated in other top-ranked infectious diseases including those caused by Adenovirus, Influenza virus, and Orthopoxvirus (Supplementary Table 4). On the other hand, the highest ranked down-regulated gene (in pattern IV) across all dpi was Bex2 (brain-expressed X-linked 2), while Bex1 and Bex4 trended similarly downward over the course of infection (Supplementary Table 2). Genes within the Bex family (Bex1, 2, 3, 4, 5, 6) are highly conserved in mammals and are expressed in a wide range of tissues [51]. Bex2 has been described as an oncogene and a dormant cancer stem cell-related protein [52, 53]. Knockout of Bex2 was studied in lung, where pathway analysis showed impacts on genes associated to oxygen carrier activity, PPAR signaling, immune response, and complement and coagulation cascades [54]. Although Bex2 remains relatively understudied in the literature to date with under 100 PubMed articles, the omic-scale data in BSCE produced 5395 Curated Studies containing 14 278 Biosets for Bex2 from a wide range of experimental designs (Supplementary Table 5). SARS was the most highly correlated phenotype for Bex2-containing biosets and was also down-regulated in other top-ranked infectious diseases, including Sendai virus infection, Stachybotryotoxicosis, Legionella infection, and Disease due to Paramyxoviridae (Supplementary Table 6).
Other high-ranking up-regulated chemokine transcripts included Cxcl9 (17th out of the 10 564 meta-signature gene total) and Cxcl11 (25th) complementing Cxcl10 expression (Fig. 3C). These three chemotactic cytokine genes are conserved as a tandem paralog set on chromosome 5q in M. musculus and chromosome 4q21 in H. sapiens [55]. They are predominately induced by interferon γ and secreted as part of a broad immune response to escalate host defenses and attract a variety of white blood cell types to sites of infection and to tumors [56, 57]. The chemokine receptor CXCR3 is the cognate partner for these ligands, where binding activates pathways along the CXCL9, 10, 11/CXCR3 axis that lead to particular intracellular signaling events and systemic immune responses [58, 59]. In combination, CXCL10 and CXCR3 are important for leukocyte migration to inflamed tissues [60]. Temporal RNA expression of Cxcr3 in SARS-CoV-1-infected mouse lung appears delayed with a sharp rise at 7 dpi, contrasting to 2 dpi peaks for its ligands (Fig. 3C, upper panel) and coincides with infiltration of macrophages and lymphocytes late in lung infection at a time when viral titers drop in the mice [46, 47] The appearance of CXCR3 at the infection site may be a biomarker for recovery.
The timing of transcriptional events was investigated by viral dose, viral variant, and host age group. Cxcl10 up-regulation shifted to earlier dpi with increasing viral dose in adult mice (Fig. 3C, lower graph). Neither severity of viral variant nor young vs. aged animal comparisons showed an effect on Cxcl10 temporal scores (Supplementary Table 1). In contrast, Bex2 expression inversely mirrored that of Cxcl10. Increasing viral dose was associated with an earlier onset in the suppression of Bex2 expression, reaching maximal down-regulation at 7 dpi (Fig. 3D, upper graph). In an opposite regulatory fashion, both Cxcl10 and Bex2 expression levels appear to be molecular readouts of viral burden (Fig. 3A, profile chart).
Host age and the severity of viral variant had an effect on Bex2 expression. Down-regulation of Bex2 occurs earlier in infection for young and aged mice treated with the most severe SARS-CoV-1 variant (MA15) compared to the weakest variant (MA15e) (Fig. 3D, lower graph). The study with the highest correlation to increased expression of Bex2 in BSCE focused on human epithelial cells exposed to hypoxic (2% O2) stress. In this study, Bex2 expression increased 5.6- and 4.8-fold over control levels after 12 and 48 h, respectively (GSE136908) [61]. The protein–protein network software STRING [33] was used to derive deeper insight into Bex2 and the 15 genes within the most highly down-regulated genes in the Bex2-containing cluster IV (See Fig. 3B). Though few direct relationships were observed for Bex2, it was connected to the G protein-coupled receptor associated sorting proteins Gprasp1 and Gprasp2. Both were strongly down-regulated across meta-signature time points (Supplementary Table 2). These genes modulate lysosomal sorting and target a variety of G-protein coupled receptors for lysosomal degradation while a lack of GPRASP2 was shown to enhance cell survival [62, 63]. Moreover, the top phenotype in the BSCE Disease Atlas for Gprasp2 was down-regulation in SARS (data not shown). A highly connected hub marked by cluster IV genes Aox3 and Pon1 also included Acss1, Aldh2, Aldh6a1, Cat, Cyp1a1, Cyp2f2, Ephx1, Gsta2, Gsta3, Gstm1, and Gstm3. All of these genes were down-regulated in the 2, 4, and 7 dpi meta-signatures (Supplementary Table 2). Decreased expression of the hub genes would functionally impair their ascribed antioxidant and toxic chemical clearance activities. As aging leads to general loss of redox control and a well-functioning oxidative stress response, down-regulated Bex2, cluster IV genes and the 13 gene hub may serve as biomarkers for severe coronavirus-induced decline [64, 65].
Cytokine ligands and receptors are expressed at low levels under homeostatic conditions. With cytokines such as Cxcl10, its activity can be induced by a variety of innate IFN-α/β and adaptive IFN-γ signals, whereas other chemokines such as Cxcl9 are limited to adaptive IFN-γ responses [66]. Figure 4A shows the temporal scores for a variety of interferons, interferon receptors, interferon-stimulated genes, and interferon regulatory factors. Interferons Ifna1, Ifna2, Ifna4, Ifna12, and Ifnab showed sharp increases in expression, peaking at 2 dpi while absent at 4 dpi and 7 dpi, whereas expression for Ifnb1 and Ifng were sustained into 4 dpi and beyond. Interferon-stimulated genes Isg15 and Isg20 had notable up-regulation spanning early and late periods. Interferon regulatory factors Irf1 and Irf2 were observed early, while Irf7 and Irf9 spanned early and late periods and Irf5 appears at 2 dpi declining into 7 dpi. Interferon receptor genes did not dramatically change across the meta-signature time course, though Ifnar1 induction occurred early while Ifngr2 was late. While the observed bulk tissue patterns noted here are complex, and many reminiscent of the Cxcl10 pattern, they provide a foundation to superimpose findings with finer resolution single cell and temporal biomarker technologies.
Figure 4.
Analysis of potential downstream pathway regulators during coronavirus infection. (A) The table shows a summary of the temporal gene scores for interferon related genes across dpi. The graph shows the temporal gene score profiles for selected interferon and interferon receptor genes as colored in the left table. (B) The directional gene scores underlying data in graph (A) was analyzed for young or aged mice by viral variant (left graph), and adult mice by viral dose of the MA15 variant (right graph). (C) The graph shows the temporal gene score profiles for genes of the Stat transcription factor family. All plots show the mean of the directional gene score and directional gene score where adequate replicates were available ±SE.
Unlike Cxcl10, age effects between young and aged mice were observed for the interferon and interferon receptor genes. Peak differences in directional gene scores were seen earlier in aged mice than in young mice for Ifna1, Ifnb1, Ifng, Ifnar1, Ifnar2, and Ifngr2 (Fig. 4B, left). Data were not available for aged mice beyond 2 dpi due to the lethality of the MA15 viral variant [28, 67]. A similar trend toward earlier maximal expression was evident for the same interferon genes and their receptors with increasing viral dosage (Fig. 4B, right). The extracellular binding of cytokines to cytokine receptors commonly activates cytoplasmic STAT transcription factors in cell-specific contexts [30, 68]. The downstream intermediaries Stat1 and Stat2 showed high RNA up-regulation with temporal gene scores that peaked at 2 dpi (Fig. 4C). Increasing MA15 viral dose in adult mice resulted in an earlier onset of Stat1 and Stat2 induction in lung; however, no temporal change was observed for the MA15 variant in young vs. adult vs. aged mice (Supplementary Fig. 2). In these regards, Stat1 and Stat2 induction patterns were similar to Cxcl10.
The use of the BSCE Knockdown Atlas further elucidated the relationships between immune response genes during SARS-CoV-1 lung infection. For these analyses, the 2 dpi temporal meta-signature, comprised of 4911 genes with temporal gene scores, was correlated to published knockout models. This analysis revealed nine knockout models of Infar1 and five knockout models of Stat1 had high negative correlations to the 2 dpi meta-signature providing further evidence for impacted gene sets (Supplementary Table 7). Studies using the knockout of Stat1 proved to be particularly informative to interpret the host immune responses inherent in the temporal meta-signatures. One of these studied the course of SARS-CoV-1 lung infection with 100 000 pfu of the MA15 variant in Stat1 deficient vs. wildtype mice (GSE36016) [69]. An inverse in the direction of expression, from up-regulated to down-regulated, was observed in 142 of the 148 common genes in the Stat1 knockout bioset compared to the 2 dpi meta-signature (P = 6.7E-107) (Supplementary Fig. 3A). In support for the relevance of Stat1 regulatory effects, the top two functional enrichment GO biogroups in Stat1 deficient vs. wildtype mice were down-regulation of both “innate immune response” (P = 1.1E-43) and “response to virus” (P = 2.3E-52) (Supplementary Fig. 3B and C). Cxcl10 RNA expression was the top up-regulated gene in the 2 dpi lung-infected vs. mock-infected meta-signature with an average fold change of 288 from four independent experiments, while in the Stat1 knockout vs. wildtype bioset Cxcl10 was reversed with down-regulation at −1.35-fold (P = .0065). While the Stat1 knockout had no effect on Bex2 expression, correlations with reversed expression were observed for high-ranking genes across the temporal meta-signatures, including the interferon-inducible antiviral response regulators Mx1 and Mx2 [70, 71] and other chemokines (e.g. Cxcl11, Cxcl9, Ccl5), interferon regulatory and stimulated genes, including Ifit2, Irf7, Ifi44, and Ifit1. Reversed, anti-correlated RNA expression was observed for 2′-5′ oligoadenylate synthetase family genes (Oas1a, Oas1b, Oas1f, Oas2, Oas3, Oasl1, Oasl2) that trigger viral RNA degradation [72, 73]. Stat1 knockout reversed expression of Schlafen genes (Slfn3, Slfn4, Slfn5, Sfln10) that function in cell proliferation, induction of immune responses, and regulation of viral replication [74–76] (Supplementary Table 7). In total, Stat1 is shown to be a critical upstream transcriptional regulator of diverse functional pathways. In addition to the abrogation of gene expression noted, Stat1-/- young mice infected with the most severe MA15 variant were unable to clear the infection, accompanied by elevation of neutrophils, eosinophils, and macrophages, acute respiratory distress, and pulmonary fibrosis resulting in death [30]. Under the same conditions, interferon alpha and beta receptor subunit 1 knockout, Ifnar1-/-, mice cleared the virus following a similar course as wildtype mice based on viral titer, weight loss, and lung immune-histochemistry results [69]. Hereby, Stat1 can be considered a central mediator of SARS-CoV-1 infectivity in mouse lung and is necessary for recovery.
Functional enrichment of temporal Meta-Signatures
Challenges to proposing biological roles of individual genes within the SARS-CoV-1 temporal meta-signatures include the dynamic mixture of cell types and cell states in the lung samples. Functional enrichment analysis using well-structured ontological concepts provides insights to pathway level activities, which can mitigate some limitations of assigning biological processes to single genes. The five temporal meta-signatures were thus passed through the BSCE Pathway Enrichment application using correlations to GO biogroups [31, 32]. Exported results were aggregated into a table comprising 2357 biogroups with directional signs and sorted by the average of the BSCE-generated raw score ranks (Supplementary Table 8). The top five biogroups were “regulation of cytokine production,” “innate immune response,” “cell activation,” “inflammatory response,” and “response to virus” (Fig. 5A), consistent with expected biology of coronavirus infection [77, 78]. The biogroup score profiles for the top four genes in “Response to virus” across the meta-signatures (Ccl4, Oasl1, Oas2, and Stat1) rise in expression from 0.5 dpi to a peak at 2 dpi followed by progressively small declines between 4 and 7 dpi (Supplementary Table 2). Examples of other functional gene sets perturbed during infection included correlations to lipid, peroxisome, and cell cycle processes. Subsets of “lipid binding” genes show activities rising through to 2 dpi then tailing off, while other “lipid binding” subsets decrease from 0.5 to 7 dpi, and the more specific child concept of “fatty acid metabolic process” is distinctively more down-regulated (Fig. 5B). Acod1, immunoresponsive gene 1, was the top-ranked “fatty acid metabolism” gene, it was up-regulated across all dpi (Supplementary Table 2) and may be a new target for therapeutic intervention [79, 80]. “Peroxisome” biogroup activities were also largely down-regulated by viral infection peaking early at 1 dpi and may constitute a novel target hijacked by SARS-CoV-1 (Fig. 5C). Fabp1 was the top-ranked “peroxisome” gene, and it was second to Bex2 as the most down-regulated gene across the temporal meta-signatures (Supplementary Table 2). A loss in host defenses due to decreased energy utilization from dysregulated fatty acid metabolism and the protection from oxidative stress afforded by Fabp1 subverts its role in resistance to infection [81, 82]. Cell division concepts also show significant temporal changes. A gradual increase in up-regulated gene expression was evident in genes from “regulation of G1/S phase transition” during infection. This was in stark contrast to genes in “regulation of G2/M phase transition,” “sister chromatid cohesion,” and “cell cycle DNA replication,” which significantly increased in expression after 2 dpi (Fig. 5D).
Figure 5.
Pathway enrichment analyses across SARS-CoV-1 temporal lung infection meta-signatures. The five temporal meta-signatures were passed through the BSCE pathway enrichment application using correlations to GO biogroups. Exported correlation lists were aggregated into a table comprising 2357 concepts with directional signs and sorted by the average of the BSCE generated raw score ranks (Supplementary Table 8). (A) The panel shows the top eight GO biogroups. (B) The panels show the mixed regulation observed between “lipid binding” and “fatty acid metabolic process”. The blowout panel shows the correlation to the 7 dpi meta-signature. (C) The left panel shows the “peroxisome” gene expression trends, whereas the blowout shows correlation to 7 dpi meta-signature. (D) The panel shows the correlations to cell cycle biogroups, while the blowout shows the correlation to the 7 dpi meta-signatures to “regulation of cell cycle G2/M phase transition”.
Temporal changes in cell cycle regulation were explored further given the distinctive rise of G2/M phase genes late in infection (Fig. 5D). Meta-signature data were filtered by the 1311 gene GO “cell cycle” biogroup, resulting in 975 genes whose expression fluctuated over the infection time course (Supplementary Table 9). Unsupervised hierarchical clustering confirmed distinctive changes in gene expression between the early (1–2 dpi) vs. late (4–7 dpi) time points (Fig. 6A), which suggested dynamic shifts in the regulation of the cell cycle between the peak of viral production and subsequent viral clearance (See Fig. 3A). This is exemplified by the expression pattern of the proliferation markers Ki67 (Mki67) [83], Pcna [84], Ccna2 and the minichromosome maintenance complex genes Mcm2 and Mcm6 [85, 86], which peak late in infection (Fig. 6B, Cell Cycle panel). This was also the pattern observed with Ccnb1 and Aurka, both of which are known to define G2/M phases of the cell cycle [87, 88]. In contrast, Ccnd2 peaked by 2 dpi, but was unchanged in the late stages. These observations help to underpin the results shown in Fig. 5 and indicate an early G1/S cell cycle arrest during infection, followed by a shift to G2/M phases during viral clearance.
Figure 6.
Temporal shift in cell cycle patterns during SARS-CoV-1 infection. (A) Temporal meta-signature results were correlated to the 1311 gene GO “cell cycle” biogroup using the BSCE pathway enrichment application. The resulting 975 genes across the 5 dpi timepoints were clustered by unsupervised methods using Euclidian distance and nearest neighbors’ agglomeration. (B) Genes from (A) that showed temporal shift were further analyzed by functional enrichment of GO and molecular pathways using WebGestalt [34, 35]. Distinct temporal patterns were revealed in classical proliferative markers, cellular stress response, DNA Damage/repair pathways, and chromosome attachment associated complexes (CPC, chromosome passenger complex; SAC, spindle assembly checkpoint). Mean values ± SE are shown. (C) Up-regulated cell cycle genes in early (1, 2 dpi) and late infection (4, 7 dpi) were analyzed for physical complexes by the STRING protein–protein network application using high confidence evidence from the literature. Unconnected nodes are not shown. Roman numerals indicate complexes of interest (see text for discussion of hubs).
Activation of stress response pathways by genes such as the Schlafen family protein Slfn1 and the cyclin inhibitor p21 (Cdkn1a) may induce a G1/S cell cycle arrest. Coinciding with peak viral load, the expression of Slfn1 and Cdkn1a peaked by 2 dpi but remained elevated throughout infection (Fig. 6B, Stress Response panel). Slfn1 has been shown to inhibit Cyclin D in several cell types [89–91]. The p21 protein can arrest cells at G1, S, or G2 phases in response to the activation of the cellular stress sensors such as p53 [92–94]. The stabilization of the p53 (Trp53) protein can arrest cells or induce programmed cell death [95]. In the temporal meta-signature data, p53 expression was elevated late in infection (Fig. 6B, Stress Response panel). However, p53 is continually transcribed, but its protein levels are kept in check by proteolytic turnover, which under cellular stress stabilize protein levels [95]. Expression of p21 may be indicative of increased p53 activity early in infection. Lastly, the CDK2 inhibitor, Cdkn3 also accumulated late in infection. Cdkn3 has an essential role in the cell cycle by regulating the G1/S transition and spindle assembly check point in M-phase [96], however, it can also affect Mdm2/p53 interactions to antagonize p21 activity [97]. Thus, Cdkn3 may suppress or promote cellular proliferation depending on cellular context.
Analysis shown in Fig. 5D revealed the enrichment of “cell cycle DNA replication” and “sister chromatid cohesion” events late in infection. DNA replication processes are associated with S phase and by the activation of repair pathways following DNA damage and replication stress. In the temporal meta-signature data, genes such as Clspn, Brca1/2, and Chek1/2 [98] (Fig. 6B, DNA Damage Response/Repair panel) were up-regulated from 4 to 7 dpi, suggestive of the activation of DNA damage responses (DDR), while the concomitant up-regulation of genes like Cdca5(Sororin), H2afx, Rad51, and Smc6 implicates the recovery from DNA damage [99, 100]. On the other hand, cohesion of sister chromatids is a dynamic process regulated by genes such as Cdca5, Cdca8(Borealin), Plk1, Sgo1, and Sgo2a [100, 101], which were up-regulated late in infection (Fig. 6B, bottom graphs). Sister chromatid adhesion also has an important role in repair from DNA damage [102]. Following a similar pattern, kinetochore and microtubule genes were also up-regulated late in infection. These genes include the chromosome passenger complex (CPC) members (Aurkb, Incep, Birc5, Cdca8(Borealin), kinetochore associated genes (Ndc80, Kntc1, Plk1), and Spindle Assembly Checkpoint (SAC) associated genes (Bub1, Bub1b, Mad2l1) [103, 104]. Together, the complexes patrol the metaphase–anaphase transition, preventing the onset of anaphase until all chromosomes are properly bi-oriented under tension between opposing spindle poles [104]. This helps to ensure the faithful inheritance of sister chromatids to daughter cells. Persistent activation of the SAC can result in mitotic arrest. Last, there is emerging evidence that connects DDR signaling and function with that of the SAC to maintain genomic integrity [105].
STRING was used to further explore putative physical mitotic complexes between early vs. late infection. As shown in Fig. 6C, few mitotic complexes were up-regulated and common between 1 and 2 dpi (Fig. 6C, hub I). Notably, these complexes included Cdkn1a and Ccnda, which highlights a possible G1 cell cycle arrest early in infection. In comparison, genes common to 4 and 7 dpi were suggestive of complexes associated with Aurka and tubulin dynamics (hub II), Cdk1/CcnB1 (hub III), and the already discussed SAC signaling (IV), DNA replication (hub V), and DNA damage responses (hub VI). The number of potential cell cycle complexes was comparable between down-regulated genes early vs. late infection (Supplementary Fig. 4). Of note, SEPTIN genes (Sept3, Sept4, Sept8) were down-regulated throughout infection. SEPTINS are less well understood than other cytoskeletal proteins but have roles in a variety of cell functions including anaphase of mitosis, cytokinesis, cell death, and immune system function [106]. Overall, analyses of cell cycle genes and potential complexes show a distinctive pattern of cellular stress related to viral infection.
Meta-signature correlations to human COVID-19 transcriptomes
Human COVID-19 single cell RNA sequencing (scRNAseq) studies (n = 4) were imported into BSCE to assess cell-type-specific contributions to host infection and the extent to which the SARS-CoV-1 murine temporal meta-signatures correlate to SARS-CoV-2 infection in H. sapiens. Given the attention paid above to resolving the underlying biological mechanisms of two up-regulated meta-signature clusters from Fig. 3B, each was correlated to the cell-type-specific expression profiles from scRNAseq published data. The first cluster was the 14 gene cluster highly up-regulated throughout infection containing Cxcl10 (Fig. 3B, cluster III), it correlated highest to “defense response to virus” with 10 common genes (P = 3.7E-25) (Supplementary Table 10). The second cluster contained 28 genes highly up-regulated at 4–7 dpi with no significant expression changes at 0.5–2 dpi (Fig. 3B, cluster II), it correlated highest to “cell division” with 18 common genes (P = 3.50E-34) (Supplementary Table 10).
The 14 genes in the Cxcl10 cluster correlated to monocyte–macrophage lineages in human COVID-19 subjects (Table 1). Using bronchoalveolar lavage fluid from healthy, moderate, and severe COVID-19 subjects, Liao et al. found severe cases contained higher proportions of macrophages and defined four macrophage groups based on RNA expression patterns [41]. The Cxcl10 14 gene cluster correlated highest, with 12 genes in common to IFN-γ differentiated M1-like macrophages that promote inflammation by secreting cytokines and chemokines (P = 3.70E-21). Results from three independent scRNAseq studies using peripheral blood mononuclear cells from COVID-19 subjects revealed the Cxcl10 cluster correlated highest with (i) 10 genes in common to CD163hi Monocytes-Cohort 1-Cluster 2 in Schulte-Schrepping et al. [42] (P = 1.90E-15), (ii) nine genes in common to the severe COVID-19 up-regulated gene set in Lee et al. [44] (P = 2.3E-15), and (iii) six genes in common to CD16 Monocyte-Cluster28 in Wilk et al. [43] (P = 1.70E-07). See Supplementary Table 11 for gene-level details containing the correlation results. An expression matrix with Cxcl10 cluster genes and top scRNAseq correlations to the four human COVID-19 studies are in Table 2. The interferon-stimulated gene ISG15 stands out as having the highest fold change in severe COVID-19 patients and is strongly represented in the three other COVID-19 scRNAseq studies. The SARS-CoV-1 temporal gene scores for the interferon-stimulated gene Isg15 are shown in Fig. 4A. Lee et al. [44] also observed ISG15 commonly up-regulated in post-mortem COVID-19 lung tissue. As such, the 14 genes in the Cxcl10 cluster may constitute a good multi-gene biomarker for early and late infection risk for severe COVID-19.
Table 1.
Gene expression matrix for the 14 gene Cxcl10 up-regulated cluster and top single cell RNAseq correlations to four human COVID-19 studies.
|
The values for the Cxcl10 cluster come from the average temporal gene score (Supplementary Table 2). The values for the four scRNAseq studies are from the reported fold changes, while the P-values are from BSCE bioset–bioset correlations. Custom colors were applied to accentuate the differences from high to lower values.
Table 2.
Gene expression matrix with the 28 gene 4-7 dpi up-regulated cluster and top single cell RNAseq correlations to four human COVID-19 studies.
|
The values for the 4-7 dpi up-regulated 28 gene cluster come from the average temporal gene score (Supplementary Table 2). The values for the four scRNAseq studies are the reported fold changes from source articles, while the P-values are from BSCE bioset–bioset correlations. Custom colors were applied to accentuate the differences from high to lower values.
The 4–7 dpi up-regulated 28 gene cluster was also correlated to the four COVID-19 scRNAseq studies: 25 of the 28 genes in this cluster correlated highest to those observed up-regulated in Proliferating T cells in Liao et al. [41] (P = 2.2E-36); 17 of 28 genes in Proliferating cells-Cohort 2-Cluster 12 in Schulte-Schrepping et al. [42] (P = 3.2E-19); 5 of 28 genes in Proliferative Lymphocytes-Cluster13 in Wilk et al. [43] (P = 7.0E-06) (Supplementary Table 12). The prevalence of up-regulated kinase genes highlights a prominent activation of intracellular signaling processes in late-stage infection (Aurka, Aurkb, Cdk1, Tk1, Plk1, Pbk, and Melk), as described previously in this article. While the observation of proliferating cells correlating to the 28 gene cluster is interesting, its impact on COVID-19 patient decline or recovery needs further study.
Temporal meta-signature correlations to drug treatments
The preceding analyses provided novel insights into the host transcriptomics and systems biology of temporal coronavirus lung infection. The analyses also described the relevance of the molecular etiology to human SARS-CoV-2 infection. Given the need for development of targeted, stage-specific treatments for COVID-19 and future coronavirus infections, the BSCE Pharmaco Atlas application was used to obtain a matrix of compound correlations to the temporal meta-signatures. This resulted in the identification of 1706 compounds with effects on gene expression either positively or negatively correlated to the SARS-CoV-1 meta-signatures (Supplementary Table 13). Positive correlations indicate compounds have similar RNA expression activities as those induced by SARS-CoV-1 lung infection. Compounds exhibiting a negative correlation have inverse effects on post-infection gene expression activities, as in up-regulated “infected vs. uninfected” genes are inversely observed as down-regulated in independent “treated vs. control” biosets, thereby exhibiting potential in alleviating mechanisms gone awry in SARS [107]. Representing immunologic intervention, there were 10 Biologic—Immune Factor Antagonists and 17 Immunological Factors. Representing intracellular signaling cascades, there were 3 Biologic—Kinase Antagonists and 66 Small Molecule Kinase Inhibitors. Other interesting Compound Classes included Immunosuppressive drug and Anti-parasite, EZH2 inhibitors, Topoisomerase Inhibitors, DNA Methyltransferase Inhibitors, Nucleoside inhibitors, Histone Methyltransferase inhibitors, Histone Deacetylase Inhibitors, Phosphatase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Glucocorticoids, Estrogenics, Androgenics, DNA Intercalators, Tubulin Disruptors, PPAR agonists—Fibrates, PPAR agonists—Glitazones, Statins, and Natural Products like beta-cryptoxanthin and aloe. The diversity of compound mechanisms of action reflects the breadth of viral-induced dysregulated functions that evolve from early to later stages of infection.
Furthermore, spanning the broad array of mechanisms were 24 correlated compounds in clinical trials for COVID-19 (Table 3). Attention was drawn to the compounds with negative correlations across time. Small molecule and biologic kinase inhibitor targets included 3 TNF antagonists, 2 JAK inhibitors as well as IL17A, IL1 receptor, and SYK and BTK inhibitors. Dexamethasone had strong negative scores across all time points, while Hydroxychloroquine had strong negative scores only at 1, 2, and 4 dpi that emphasize the potential to specifically target early viral accumulation and subsequent clearance stages based on ensemble transcriptomic analyses.
Table 3.
Compound correlations to SARS-CoV-1 lung infected temporal meta-signatures in COVID-19 clinical trials.
|
BSCE Pharmaco Atlas assigns the highest ranking compound a score of 100 in each of the five temporal meta-signatures. Lesser ranking compounds at each time point are linearly normalized to the highest ranking compound, as described in section “Methods”. A directional sign is added to reflect a positive (yellow) or negative (blue) correlation. Compounds known to be in clinical trials were derived from https://ghddi-ailab.github.io/Targeting2019-nCoV/clinical. The entire list of all 1706 significantly correlated compounds from the BSCE Pharmaco Atlas and an annotated list of other interesting compounds is in Supplementary Table 13.
Supervised machine learning on 74 SARS-CoV-1 biosets and COVID-19 in silico biomarker validation
Based on the findings above, an orthogonal informatics approach was performed to define a minimal gene set that could distinguish stages of coronavirus host response using elastic-net logistic regression combined with bootstrapping [38, 39]. This supervised machine learning method started with 100 random splits of the 74 biosets into two groups based on early (0.5–2 dpi) and during the viral clearance stage of infection (4–7 dpi). Regularization was implemented to avoid overfitting because the number of sample biosets (n = 74) was much smaller than the number of genes (10 564) in the dataset. The elastic-net method, which combined L1 and L2 regularization, has the flexibility in selecting the feature genes by tuning the hyperparameter “C” and “l1_ratio” (see section “Methods”). Bootstrapping 100 times on random 80% training and 20% test bioset splits (Fig. 7A) yielded 21 genes present in >90 of the bootstraps with accuracies and directional weights (Fig. 7B and C). Genes were ranked by the average weights in the model. A gene with a higher negative average weight means it is relatively more important in the model in predicting the sample is at an early stage, while higher positive weights predict a sample is at late stage. Six genes were predicted as early and 15 genes as late. The directional gene scores from the 74 biosets are shown in the heatmap where up-regulation dominates final assignments. A network diagram of associations based on literature assertions rendered in Pathway Studio shows connections of gene relationships spanning early-stage extracellular factors (Adm, Il1a) with subsequent plasma membrane (Gbp2), cytosolic (including Cdk1, Birc5) and nuclear localization (including Mik67, Top2A) (Fig. 7D and Supplementary Table 14).
Figure 7.
Supervised machine learning on 74 SARS-CoV-1 biosets and COVID-19 in silico biomarker validation. (A) The panels show the results of training and test accuracy scores across the 100 bootstraps. (B) The heatmap shows the 21 genes present in >90 of the bootstraps horizontally ordered by dpi with the accuracies and directional weights. (C) The table lists the results with annotated gene function. Note the preponderance of cell cycle genes in late infection. (D) The relationships between the 21 gene panels were analyzed with Elsevier’s Pathway Studio. (E) The temporal data from Filbin et al. [45] were re-analyzed for adrenomedullin (ADM) within five profiles for escalating WHO Max categories. Mean values ± SE are shown. The left panel shows ADM protein levels in plasma from COVID-19 humans by severity level, whereas the right panel shows ADM protein levels by severity within age groups.
Functional enrichment analyses were done on the host response stage predictor 21 gene set using the BSCE Pathway Enrichment application (Supplementary Table 15). Because there were only six early genes, functional biogroups were not highly populated, however, “negative regulation of gene expression, epigenetic” was the top GO biogroup represented by Mdb1 and Znfx1 (P = 7.7E-6). The top two functional enrichments for the late genes identified eight genes associated to “cell division” (P = 1.30E-14) and six genes associated to “chromosome segregation”: Cdca5, Ncapg, Ska1, Top2a, Cdca8, and Birc5 (P = 3.90E-12). The importance of cell cycle genes late in coronavirus infection was also evident in the analysis of temporal meta-signatures (Figures 5 and 6). The most predictive late gene, Cdca5, cell division cycle associated 5 and also known as Sororin, was found in each of these biogroups and is understudied in the literature to date. Cdk1 was also a late-stage predictor gene. Sororin is regulated by G2/M kinase complexes associated with Cdk1 and Aurkb [108]. Cdca8 (Boreallin) and Birc5 (Survivin) along with Aurkb are integral components of the CPC, which was discussed in the context of Fig. 6B as regulating cell cycle events associated with kinetochore and microtubule dynamics late in coronavirus infection [103, 104]. It was then remarkable to find that the AURKB inhibitor Barasertib with strong negative correlations across the temporal meta-signatures and is in COVID-19 clinical trials (Table 3). Combined, these observations further support altered cell cycle states are a defining characteristic of SARS-CoV-1 late host responses.
Adm, the top early gene, encodes the circulatory hormone adrenomedullin, it has been identified as a potential biomarker in COVID-19 [109, 110]. This prompted the exploration of ADM activity in published human data where the Olink proteomics technology was used to analyze the plasma of COVID-19 patients. Filbin et al. divided patients into five categories of increasing disease progression over multiple time points with WHOmax as the patient’s most severe state [45]. Consistent with the current study, ADM protein levels were found highly elevated, especially in patients with the highest WHOmax categories. Notably, ADM was maximally elevated in patients who died within 28 days of being admitted to hospital (Fig. 7E, left). Furthermore, elevated ADM levels were associated with increasing age, as was particularly evident in patients over 65 years old and died after 28 days (Fig. 7E, right).
Plasma proteomes measure a blend of systemic contributions from resident and circulating immune cells and from damaged tissues (e.g. lung, heart, kidney, brain). The strategies and results presented culminate in an unexpected discovery, where a crowdsourcing, ensemble approach using SARS-CoV-1-infected mouse lung RNA expression led to adrenomedullin, a novel protein biomarker of human SARS-CoV-2 infection and COVID-19 severity in blood.
Discussion
Wisdom of crowds
Crowdsourcing of curated transcriptomic data, standard bioinformatics, and advanced machine learning approaches were used to address three major questions leveraging publicly available SARS-CoV data sets: (i) which genes and functional pathways are dysregulated during coronavirus infection; (ii) which genes and gene sets could be used as predictive biomarkers; and (iii) what compounds may counteract pathogenic processes? To address these questions, a meta-signature development approach was described to discover time-dependent host infection mechanisms and shed light on potential therapeutic interventions. This approach can be adapted to any disease with sufficient RNA transcription data. However, there are several limitations to the approach presented in this study: (i) only RNA expression data were used to measure the biological responses and create temporal meta-signatures for host-infected lung tissue. As such, translational regulation and protein activities may not correlate to RNA levels of respective genes, (ii) only lung tissue was used which may not be a proxy for systemic impacts beyond the lung, (iii) a mouse model with mostly unnatural SARS-CoV-1 variants may not accurately recapitulate naturally evolved causes of disease in humans and other hosts, (iv) the use of only female mice across all available studies leaves open questions of mechanistic differences in males, (v) BSCE used absolute fold change to rank differential expression, which minimizes genes lacking a large dynamic range, and (vi) there are many mathematical strategies and software solutions to perform meta-analysis [111], and is especially true in the fields of omics-scale bioinformatics and translational health science [112–114]. Despite these limitations, the approaches used generated novel insights, some of which were corroborated by SARS-CoV-2 data. By making the data readily available and interactive, the authors encourage public efforts using it to investigate and make scientific impacts that alleviate morbidity induced by emerging SARS-CoV variants.
Interferons, cytokines, and stat signaling in host response to coronavirus infection
Immune responses to coronavirus infection have taken the center stage as severe COVID-19 has been associated to an out-of-control “cytokine storm” [48]. Under homeostatic conditions, the innate and the adaptive immune response pathways are quiescently held in wait. A complete assessment of the systemic, intercellular, and intracellular factors that influence the course of immune-mediated severe respiratory disease has yet to be elucidated. However, resident and infiltrating alveolar macrophages are fundamentally implicated as they produce excessive amounts of cytokines, notably CXCL10 in cytokine storm syndromes [50]. This article provided temporal RNA expression insights to prioritize many interferon, cytokine, and intermediatory factors. A 14 gene biomarker for early and late infection risk for severe COVID-19 was comprised of an assortment of immune factors. It was proposed that this multi-gene biomarker was predominantly enacted within the monocyte–macrophage axis of response to infection.
Host age was a factor whereby young animals delayed expression of key alpha, beta, and gamma interferon and interferon receptor genes compared to adult and aging hosts. Contemporaneously, Cxcl10 and the Stat family of transcriptional activators did not appear to be affected by age. However, increasing viral dose triggered Cxcl10, Stat1, Stat2, and Stat3 expression to appear at earlier time points lending credence as early central control factors. Furthermore, Stat1 knockout abrogated SARS-CoV-1 induced Cxcl10 expression [69] adding support that some level of expression of these genes is necessary for recovery and in severe conditions avoiding death. Correlations of the temporal meta-signatures showed evidence that the JAK targeting JAK-STAT pathway inhibitors Ruxolitinib and Tofacitinib could effectively reverse coronavirus induced RNA expression activities from early to late stages. Extreme levels of CXCL10 measured in the blood of infected individuals of all ages may be a diagnostic marker suggesting JAK-STAT therapeutic intervention.
Lung airway microenvironments have a thin stromal framework with resident epithelial cells, T cells, B cells, and other antigen-presenting cells that may limit a rapid immune response and thereby enable high viral loads [115]. The interplay of infected tissue resident cells signaling innate immunity and subsequent adaptive recruitment of white blood cells to transform and infiltrate infected tissues was informed by correlations of the temporal meta-signatures to COVID-19 single cell RNAseq experiments, wherein expression of the chemotactic cytokine Cxcl10 was most highly associated to monocyte–macrophage lineages. Future spatial and single cell RNAseq studies are needed that compare bronchial lavage, tissue biopsies, and blood samples from first exposure individuals to those stricken multiple times with coronavirus. After recovery from a first infection, the stromal portfolio of cell types in alveoli changes to include memory B cells and T cells. Temporal perspectives on how these new sentinel cell types perform will further delineate well-controlled vs. out-of-control responses that may lead to permanent tissue damage.
Cell cycle in host response to coronavirus infection
Cell cycle genes showed the most dramatic changes in expression between early active viral infection and late viral clearance in the temporal meta-signature data. This pattern reflects the complicated biology of coronaviruses infecting individual cells, host viral responses, and tissue repair and return to homeostasis during viral clearance. Nevertheless, the overexpression of G2/M, DNA damage and repair response, and SAC genes late in infection have implications for long-term tissue recovery from coronavirus infection. In severely affected COVID-19 individuals, cytokine storm appears responsible for many of the complications and mortalities seen from SARS-CoV-2 infection after viral levels have dropped [116, 117]. Many of the complications associated with severe COVID-19 infections are due to multiorgan tissue damage [118, 119]. Dying cells are a source of growth factors by the “phoenix” pathway [120], which may activate resident stem cells to proliferate after tissue damage. The induction of the phoenix pathway may then allow the switch from a G1/S cell cycle arrest early in infection when viral production peaks to a more proliferative G2/M gene expression profile during viral clearance.
Dying cells may also account for up-regulation of DNA damage and repair response and SAC genes during the viral clearance stage of infection in the meta-signature data. Previous studies have shown that dying cells release DNA fragments, so-called cell-free DNA (cfDNA), from the nucleus and mitochondria after severe infection or sepsis [121]. Uptake of cfDNA by healthy cells can lead to DNA double-stranded breaks and DNA damage response [122]. More important, cfDNA acts as damage-associated molecular patterns that trigger inflammation [121]. On this track, Shabrish and Mittra proposed that cfDNA from severe COVID disease may be responsible for cytokine storm and worst patient outcomes [123]. Supporting this hypothesis, serum cfDNA levels were recently correlated with inflammation, kidney tissue injury and worst disease progression and mortality in COVID-19 patients [124]. Thus, the temporal meta-signature data may, in part, reflect the effects of cfDNA during the recovery phase of coronavirus infection. It is also important to note that the DNA repair process can be error-prone, leading to chromosomal abnormalities, and incorporation of mutations [102]. Moreover, recent studies have begun to appreciate the role of genetic mosaicism, the heterogenous genetic changes that are present or accumulated across an individual tissue, in the progression of a variety of diseases including cancer [125, 126]. Genetic mosaicism that happens in somatic cells can increase with age or be caused by environmental factors, and likely reflects accumulation of mutations or genetic changes in resident tissue stem cells [125, 127–129]. As others have noted, there may be increased predisposition for future disease due to altered immune responses after COVID-19 [130–132]. It is likely then that genetic alterations after COVID-19 due to systemic cfDNA may contribute to future disease risk including cancer. Disease surveillance and DNA analysis of symptomatic COVID-19 survivors may be needed to mitigate any incurred risk.
Adrenomedullin in host response to coronavirus infection
Adrenomedullin, encoded by the ADM gene, was identified in this article as an early biomarker of severe COVID-19 infection by applying a machine learning algorithm to the 74 mouse lung SARS-CoV-1-infected biosets. In SARS-CoV-1-infected mouse lung, Adm RNA was up-regulated only in the early viral accumulation period and not in subsequent clearance stages. Adrenomedullin is a peptide hormone that is ubiquitously expressed in human tissues with local and systemic vasodilating properties [133, 134]. In the serum of COVID-19 patients, high ADM protein levels were detected at all WHOmax severity levels and days post hospitalization out to 28 days. Of keynote, ADM levels were progressively higher in patients with increased age and increased WHOmax level, those over 80 years old and died had the highest levels. Because it can be measured using a minimally invasive blood draw, adrenomedullin is an excellent candidate for diagnostic and treatment development. Adrenomedullin is being pursued as a predictive biomarker for a variety of diseases including cardiovascular mortality [135] and Chronic Kidney Disease (NCT05339009). Adrecizumab, a monoclonal antibody that binds adrenomedullin, attenuates oxidative stress and is a drug in clinical trials as a targeted sepsis and COVID-19 therapy [136, 137] (NCT05156671). As adrenomedullin is expressed broadly in many tissues [138], it will be interesting to know the extent to which circulating ADM derives from non-lung sources of COVID-19 subjects as other organs succumb to this syndrome.
Bex2 in host response to coronavirus infection
This study identified many single and multi-gene RNA expression biomarkers that are up-regulated coursing across stages of coronavirus infection. It is critical that down-regulated biomarkers are not overlooked as these may be direct targets affected by viral processes overriding host defense mechanisms. The X-linked gene Bex2 was the highest ranking down-regulated gene identified across the SARS-CoV-1 meta-signature time course, while Bex1 and Bex4 followed a similar trend. The BSCE omic-scale data were rich in examples for Bex2 down-regulation in a wide variety of infectious diseases and cancers. BEX2 down-regulation induced G1 cell cycle arrest and sensitized cancer cells to pro-apoptotic agents [139, 140]. It is possible that BEX genes may play a similar role during coronavirus infection, namely sensitizing infected cells or their neighbors to apoptosis. This may work via viral promotion of a pro-oxidant environment interfering with redox homeostasis and antioxidant defense systems [141].
As its gene name implies, brain-expressed X-linked 2 is located on the X-chromosome and is therefore represented as two copies in females and one copy in males. There is a well-documented gender effect on severity and mortality with COVID-19 [142–144], with males more likely to suffer more severe symptoms with higher mortality rates than infected females. It has been suggested that this gender difference is due to the immune response, with a more robust T-cell activation correlated to a better SARS-CoV-2 infection outcome in female and young patients compared to male and old patients, respectively [144]. Given that this gene is down-regulated in a variety of viral infections, it may be that Bex2 is a protective gene that is targeted for inhibition by the invading virus. A recent study in induced pluripotent stem cells has shown that Bex2 is capable of escaping X-chromosome inactivation [145], thereby giving females potentially two functional copies. It should also be noted that Bex1 and 2 were found to be colocalized with the olfactory marker protein in mature olfactory receptor neurons [146], suggesting a mechanism for loss of smell in the host after viral infection.
Therapeutics with potential to alleviate coronavirus disease severity
Precision medicine and personalized healthcare has become a standard goal in the development of therapeutic agents where biomarkers define particular treatments to subgroups of patients experiencing the same disease diagnosis [147–149]. Coronavirus infection impacts an astonishing number of normal biological processes with disease severity often dependent on the presence of comorbidities: like age, cardiovascular disease, diabetes, obesity, and cancer [150]. Often, therapeutic strategies target more than one mechanism with potent combinations aiming for improved outcomes, as it is for COVID-19 [151–153]. Several immune factor agonists, immune factor antagonists, kinase inhibitors, peroxisome proliferation agonists, and histone deacetylase inhibitors were observed to favorably anti-correlate broadly across early, mid- and late stages of infection, while compounds in other classes had a mix of early, mid-, or late effects. With access to sufficient data, it would be beneficial to study COVID-19 severity in patients taking prescription drugs that may have improved their outcome.
The cause of viral respiratory infections is not limited to members of the beta-coronavirus species [154]. Clinical presentation of symptoms can have substantial overlap whether the causative agent is influenza A or B viruses, respiratory syncytial virus A or B, respiratory enteroviruses, rhinoviruses, respiratory adenoviruses, human metapneumovirus, parainfluenza viruses, and other coronaviruses [155, 156]. Diagnosis of the causative agent is not possible based on reports of symptoms, yet a common physiology suggests that common molecular phenomena drive the course of events. Medicines that alleviate symptoms and improve host condition for one viral respiratory infection could improve the condition of patients presenting with a different viral respiratory infection [157].
Conclusions
There are several areas where additional information would better inform the value of the biomarkers and transcriptional signatures presented in this study. Incorporating data on comorbidity factors and genetic susceptibility could further refine mechanistic understanding and targeted therapeutic strategies. Layering in Structural Biology studies of coronavirus gene products using 3-D modeling and docking of host ligands would help to dynamically describe events in the viral replication and host recovery phases. A whole-body network model of host response gene programs would be aided by the addition of molecular observations across more tissues in bulk and in single cells over the course of infection and recovery. Integrating this information with the temporal meta-signature “targets” would add more dimensions and elevate opportunities for precise mechanistic intervention. As new coronaviruses will inevitably emerge, grasping the fundamental underpinnings of infection and host reactions will better position mankind to effectively blunt future disease severity and spread.
Supplementary Material
Acknowledgements
The authors thank Joseph Delaney and his team of BSCE curators at Illumina.
Contributor Information
James Flynn, Illumina Corporation, San Diego, CA 92122, United States.
Mehdi M Ahmadi, Gates Center for Regenerative Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Chase T McFarland, Bioinfo Solutions LLC, Parker, CO 80134, United States.
Michael D Kubal, Illumina Corporation, San Diego, CA 92122, United States.
Mark A Taylor, Bioinfo Solutions LLC, Parker, CO 80134, United States.
Zhang Cheng, Illumina Corporation, San Diego, CA 92122, United States.
Enrique C Torchia, Gates Center for Regenerative Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Michael G Edwards, Bioinfo Solutions LLC, Parker, CO 80134, United States.
Author contributions
James Flynn (Conceptualization [Lead], Data curation [Lead], Formal analysis [Lead], Funding acquisition [Lead], Investigation [Lead], Methodology [Lead], Project administration [Lead], Resources [Lead], Software [Lead], Supervision [Lead], Validation [Lead], Visualization [Lead], Writing—original draft [Lead], Writing—review & editing [Lead]), Mehdi Ahmadi (Data curation [Supporting], Formal analysis [Supporting], Investigation [Supporting], Methodology [Supporting], Software [Supporting], Visualization [Supporting], Writing—review & editing [Supporting]), Chase McFarland (Data curation [Supporting], Formal analysis [Supporting], Investigation [Supporting], Methodology [Supporting], Software [Supporting], Validation [Supporting], Visualization [Supporting], Writing—review & editing [Supporting]), Michael Kubal (Conceptualization [Supporting], Formal analysis [Supporting], Investigation [Supporting], Methodology [Supporting], Software [Supporting], Visualization [Supporting], Writing—review & editing [Supporting]), Mark Taylor (Conceptualization [Supporting], Data curation [Supporting], Formal analysis [Supporting], Investigation [Supporting], Methodology [Supporting], Software [Supporting], Validation [Supporting], Visualization [Supporting], Writing—review & editing [Supporting]), Zhang Cheng (Conceptualization [Supporting], Data curation [Supporting], Formal analysis [Supporting], Investigation [Supporting], Methodology [Supporting], Software [Supporting], Validation [Supporting], Visualization [Supporting], Writing—review & editing [Supporting]), Enrique Torchia (Conceptualization [Equal], Data curation [Equal], Formal analysis [Equal], Investigation [Equal], Methodology [Equal], Project administration [Equal], Supervision [Equal], Validation [Equal], Visualization [Equal], Writing—original draft [Equal], Writing—review & editing [Equal]), Michael Edwards (Conceptualization [Equal], Data curation [Equal], Formal analysis [Equal], Investigation [Equal], Methodology [Equal], Project administration [Equal], Software [Equal], Supervision [Equal], Validation [Equal], Visualization [Equal], Writing—original draft [Equal], Writing—review & editing [Equal])
Supplementary data
Supplementary data are available at Biology Methods and Protocols online.
Conflict of interest
J.F., M.K., and Z.C. work for Illumina, the commercial developer of BSCE. M.E., E.T., M.T., C.M., and M.A. report no competing interests.
Data availability
The data and code are also available at GitHub (https://github.com/Mark-A-Taylor/Coronavirus_Portal.git/). An interactive portal is available at http://18.222.95.219:8047. Any additional information required to reproduce this work is available from the corresponding authors.
References
- 1. Gorbalenya AE, Baker SC, Baric RS. et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Shereen MA, Khan S, Kazmi A. et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Excler JL, Saville M, Berkley S. et al. Vaccine development for emerging infectious diseases. Nat Med 2021;27:591–600. [DOI] [PubMed] [Google Scholar]
- 4. Koff WC, Schenkelberg T, Williams T. et al. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med 2021;13: [DOI] [PubMed] [Google Scholar]
- 5. Lopez Bernal J, Andrews N, Gower C. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021;385:585–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80.e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Abdelrahman Z, Li M, Wang X.. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses. Front Immunol 2020;11:552909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Wu A, Peng Y, Huang B. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020;27:325–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Zhou P, Yang XL, Wang XG. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wan Y, Shang J, Graham R. et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94(7):e00127–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Zaki AM, van Boheemen S, Bestebroer TM. et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20. [DOI] [PubMed] [Google Scholar]
- 13. Li Y-H, Hu C-Y, Wu N-P. et al. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering (Beijing) 2019;5:940–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Raj VS, Mou H, Smits SL. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495:251–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006;66:193–292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Song Z, Xu Y, Bao L. et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019;11:59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Tan Y-J, Lim SG, Hong W.. Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus. Antiviral Res 2006;72:78–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Totura AL, Bavari S.. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov 2019;14:397–412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Glass GV. Primary, secondary, and meta-analysis of research. Educ Res 1976;5:3–8. [Google Scholar]
- 20. Galton F. Vox populi. Nature 1907;75:450–1. [Google Scholar]
- 21. Sparks R, Lau WW, Tsang JS.. Expanding the immunology toolbox: embracing public-data reuse and crowdsourcing. Immunity 2016;45:1191–204. [DOI] [PubMed] [Google Scholar]
- 22. Kupershmidt I, Su QJ, Grewal A. et al. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 2010;5:e13066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Barrett T, Wilhite SE, Ledoux P. et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 2013;41:D991–D995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Leinonen R, Sugawara H, Shumway M.. The sequence read archive. Nucleic Acids Res 2011;39:D19–D21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Athar A, Füllgrabe A, George N. et al. ArrayExpress update—from bulk to single-cell expression data. Nucleic Acids Res 2019;47:D711–D715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Gwinn WM, Auerbach SS, Parham F. et al. Evaluation of 5-day in vivo rat liver and kidney with high-throughput transcriptomics for estimating benchmark doses of apical outcomes. Toxicol Sci 2020;176:343–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Igarashi Y, Nakatsu N, Yamashita T. et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res 2015;43:D921–D927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Roberts A, Deming D, Paddock CD. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 2007;3:e5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Rockx B, Baas T, Zornetzer GA. et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 2009;83:7062–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Frieman MB, Chen J, Morrison TE. et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog 2010;6:e1000849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Ashburner M, Ball CA, Blake JA. et al. Gene ontology: tool for the unification of biology. Nat Genet 2000;25:25–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Ontology Resource G. The gene ontology resource: enriching a GOld mine. Nucleic Acids Res 2021;49:D325–D34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Szklarczyk D, Gable AL, Lyon D. et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607–D613. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Liao Y, Wang J, Jaehnig EJ. et al. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res 2019;47:W199–W205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Wang J, Vasaikar S, Shi Z. et al. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 2017;45:W130–W137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Galili T, O'Callaghan A, Sidi J, Sievert C.. heatmaply: an R package for creating interactive cluster heatmaps for online publishing. Bioinformatics 2018;34:1600–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Gu Z, Hübschmann D.. Make interactive complex heatmaps in R. Bioinformatics 2021;38:1460–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Barretina J, Caponigro G, Stransky N. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Zou H, Hastie T.. Regularization and variable selection via the elastic net. J Royal Stat Soc Ser B 2005;67:301–20. [Google Scholar]
- 40. Pedregosa F, Varoquaux G, Gramfort A. et al. Scikit-learn: machine learning in python. JMLR 2011;12:2825–30. [Google Scholar]
- 41. Liao M, Liu Y, Yuan J. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020;26:842–4. [DOI] [PubMed] [Google Scholar]
- 42. Schulte-Schrepping J, Reusch N, Paclik D. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 2020;182:1419–40.e23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Wilk AJ, Rustagi A, Zhao NQ. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med 2020;26:1070–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Lee JS, Park S, Jeong HW. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol 2020;5(49):eabd1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Filbin MR, Mehta A, Schneider AM. et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med 2021;2:100287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Bao L, Deng W, Huang B. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020;583:830–3. [DOI] [PubMed] [Google Scholar]
- 47. Glass WG, Subbarao K, Murphy B. et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 2004;173:4030–9. [DOI] [PubMed] [Google Scholar]
- 48. Fajgenbaum DC, June CH.. Cytokine storm. N Engl J Med 2020;383:2255–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Agostini C, Calabrese F, Rea F. et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001;158:1703–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Coperchini F, Chiovato L, Rotondi M.. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: not one for all but all for one!. Front Immunol 2021;12:668507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Alvarez E, Zhou W, Witta SE. et al. Characterization of the Bex gene family in humans, mice, and rats. Gene 2005;357:18–28. [DOI] [PubMed] [Google Scholar]
- 52. Kazi JU, Kabir NN, Rönnstrand L.. Brain-expressed X-linked (BEX) proteins in human cancers. Biochim Biophys Acta 2015;1856:226–33. [DOI] [PubMed] [Google Scholar]
- 53. Saijoh S, Nakamura-Shima M, Shibuya-Takahashi R. et al. Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein. Biochem Biophys Res Commun 2021;537:132–9. [DOI] [PubMed] [Google Scholar]
- 54. Bahadar N, Ullah H, Adlat S. et al. Analyzing differentially expressed genes and pathways of Bex2-deficient mouse lung via RNA-Seq. Turk J Biol 2021;45:588–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Lee HH, Farber JM.. Localization of the gene for the human MIG cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine "mini-cluster". Cytogenet Cell Genet 1996;74:255–8. [DOI] [PubMed] [Google Scholar]
- 56. Callahan V, Hawks S, Crawford MA. et al. The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner. Viruses 2021;13:1062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Metzemaekers M, Vanheule V, Janssens R. et al. Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Front Immunol 2017;8:1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Groom JR, Luster AD.. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Tokunaga R, Zhang W, Naseem M. et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev 2018;63:40–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Vazirinejad R, Ahmadi Z, Kazemi Arababadi M. et al. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation 2014;21:322–30. [DOI] [PubMed] [Google Scholar]
- 61. Tang X, Miao Y, Luo Y. et al. Suppression of endothelial AGO1 promotes adipose tissue browning and improves metabolic dysfunction. Circulation 2020;142:365–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Holmfeldt P, Ganuza M, Marathe H. et al. Functional screen identifies regulators of murine hematopoietic stem cell repopulation. J Exp Med 2016;213:433–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Kaeffer J, Zeder-Lutz G, Simonin F. et al. GPRASP/ARMCX protein family: potential involvement in health and diseases revealed by their novel interacting partners. Curr Top Med Chem 2021;21:227–54. [DOI] [PubMed] [Google Scholar]
- 64. Chandrasekaran A, Idelchik M, Melendez JA.. Redox control of senescence and age-related disease. Redox Biol 2017;11:91–102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Subramaniyan B, Larabee JL, Bodas M. et al. Characterization of the SARS-CoV-2 host response in primary human airway epithelial cells from aged individuals. Viruses 2021;13(8):1603–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Gordon DE, Jang GM, Bouhaddou M. et al. A SARS-CoV-2 protein interaction map reveals targets for drug-repurposing. Nature 2020;583:459–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Channappanavar R, Fehr AR, Vijay R. et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 2016;19:181–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621–51. [DOI] [PubMed] [Google Scholar]
- 69. Zornetzer GA, Frieman MB, Rosenzweig E. et al. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol 2010;84:11297–309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Haller O, Staeheli P, Kochs G.. Interferon-induced Mx proteins in antiviral host defense. Biochimie 2007;89:812–8. [DOI] [PubMed] [Google Scholar]
- 71. Sehgal PB. Metastable biomolecular condensates of interferon-inducible antiviral Mx-family GTPases: a paradigm shift in the last three years. J Biosci 2021;46(3):72–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Elkhateeb E, Tag-El-Din-Hassan HT, Sasaki N. et al. The role of mouse 2',5'-oligoadenylate synthetase 1 paralogs. Infect Genet Evol 2016;45:393–401. [DOI] [PubMed] [Google Scholar]
- 73. Pulit-Penaloza JA, Scherbik SV, Brinton MA.. Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation. Virology 2012;425:71–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Liu F, Zhou P, Wang Q. et al. The Schlafen family: complex roles in different cell types and virus replication. Cell Biol Int 2018;42:2–8. [DOI] [PubMed] [Google Scholar]
- 75. Mavrommatis E, Fish EN, Platanias LC.. The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res 2013;33:206–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Puck A, Aigner R, Modak M. et al. Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells. Results Immunol 2015;5:23–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Perlman S, Dandekar AA.. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 2005;5:917–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Zhang YY, Li BR, Ning BT.. The comparative immunological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 coronavirus infections. Front Immunol 2020;11:2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Weiss JM, Davies LC, Karwan M. et al. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. J Clin Invest 2018;128:3794–805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Wu R, Chen F, Wang N. et al. ACOD1 in immunometabolism and disease. Cell Mol Immunol 2020;17:822–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Memon RA, Bass NM, Moser AH. et al. Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta 1999;1440:118–26. [DOI] [PubMed] [Google Scholar]
- 82. Wang G, Bonkovsky HL, de Lemos A. et al. Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res 2015;56:2238–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Gerdes J, Lemke H, Baisch H. et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–5. [PubMed] [Google Scholar]
- 84. Kurki P, Vanderlaan M, Dolbeare F. et al. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986;166:209–19. [DOI] [PubMed] [Google Scholar]
- 85. Henglein B, Chenivesse X, Wang J. et al. Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci USA 1994;91:5490–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Stoeber K, Tlsty TD, Happerfield L. et al. DNA replication licensing and human cell proliferation. J Cell Sci 2001;114:2027–41. [DOI] [PubMed] [Google Scholar]
- 87. Fernandez J, Torchia EC.. Isolation and staining of mouse skin keratinocytes for cell cycle specific analysis of cellular protein expression by mass cytometry. J Vis Exp 2019; [DOI] [PubMed] [Google Scholar]
- 88. Ryan WK, Fernandez J, Peterson MK. et al. Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase. Cell Death Differ 2019;26:548–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89. Brady G, Boggan L, Bowie A. et al. Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1*. J Biol Chem 2005;280:30723–34. [DOI] [PubMed] [Google Scholar]
- 90. Kuang C-y, Yang T-h, Zhang Y. et al. Schlafen 1 inhibits the proliferation and tube formation of endothelial progenitor cells. PLoS One 2014;9:e109711. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Schwarz DA, Katayama CD, Hedrick SM.. Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity 1998;9:657–68. [DOI] [PubMed] [Google Scholar]
- 92. Brugarolas J, Chandrasekaran C, Gordon JI. et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552–7. [DOI] [PubMed] [Google Scholar]
- 93. Radhakrishnan SK, Feliciano CS, Najmabadi F. et al. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 2004;23:4173–6. [DOI] [PubMed] [Google Scholar]
- 94. Waga S, Hannon GJ, Beach D, Stillman B.. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574–8. [DOI] [PubMed] [Google Scholar]
- 95. Boutelle AM, Attardi LD.. p53 and tumor suppression: it takes a network. Trends Cell Biol 2021;31:298–310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96. Nalepa G, Barnholtz-Sloan J, Enzor R. et al. The tumor suppressor CDKN3 controls mitosis. J Cell Biol 2013;201:997–1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97. Okamoto K, Kitabayashi I, Taya Y.. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. Biochem Biophys Res Commun 2006;351:216–22. [DOI] [PubMed] [Google Scholar]
- 98. Sulli G, Di Micco R, di Fagagna FA.. Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer 2012;12:709–20. [DOI] [PubMed] [Google Scholar]
- 99. Branzei D, Foiani M.. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008;9:297–308. [DOI] [PubMed] [Google Scholar]
- 100. Schmitz J, Watrin E, Lénárt P. et al. Sororin is required for stable binding of cohesin to chromatin and for sister chromatid cohesion in interphase. Curr Biol 2007;17:630–6. [DOI] [PubMed] [Google Scholar]
- 101. Gutiérrez-Caballero C, Cebollero LR, Pendás AM.. Shugoshins: from protectors of cohesion to versatile adaptors at the centromere. Trends Genet 2012;28:351–60. [DOI] [PubMed] [Google Scholar]
- 102. Phipps J, Dubrana K.. DNA repair in space and time: safeguarding the genome with the cohesin complex. Genes 2022;13:198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. Cheeseman IM. The kinetochore. Cold Spring Harb Perspect Biol 2014;6:a015826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104. Hayward D, Alfonso-Pérez T, Gruneberg U.. Orchestration of the spindle assembly checkpoint by CDK1-cyclin B1. FEBS Lett 2019;593:2889–907. [DOI] [PubMed] [Google Scholar]
- 105. Marima R, Hull R, Penny C. et al. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. Mutat Res Rev Mutat Res 2021;787:108376. [DOI] [PubMed] [Google Scholar]
- 106. Woods BL, Gladfelter AS.. The state of the septin cytoskeleton from assembly to function. Curr Opin Cell Biol 2021;68:105–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107. Lamb J, Crawford ED, Peck D. et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929–35. [DOI] [PubMed] [Google Scholar]
- 108. Borton MT, Rashid MS, Dreier MR. et al. Multiple levels of regulation of sororin by Cdk1 and Aurora B. J Cell Biochem 2016;117:351–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109. Gregoriano C, Koch D, Kutz A. et al. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study. Clin Chem Lab Med 2021;59:995–1004. [DOI] [PubMed] [Google Scholar]
- 110. Hupf J, Mustroph J, Hanses F. et al. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit Care 2020;24:527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111. Schmid CH, Stijnen T, White I.. Handbook of Meta-Analysis. CRC Press, 2020, 571 p. [Google Scholar]
- 112. Chang L-C, Lin H-M, Sibille E. et al. Meta-analysis methods for combining multiple expression profiles: comparisons, statistical characterization and an application guideline. BMC Bioinformatics 2013;14:368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113. Hamid JS, Hu P, Roslin NM. et al. Data integration in genetics and genomics: methods and challenges. Hum Genomics Proteomics 2009;2009:869093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114. Ramasamy A, Mondry A, Holmes CC. et al. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med 2008;5:e184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115. Hussell T, Goulding J.. Structured regulation of inflammation during respiratory viral infection. Lancet Infect Dis 2010;10:360–6. [DOI] [PubMed] [Google Scholar]
- 116. Castelli V, Cimini A, Ferri C.. Cytokine storm in COVID-19: “When you come out of the storm, you won’t be the same person who walked in”. Front Immunol 2020;11:2132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117. Stankiewicz Karita HC, Dong TQ, Johnston C. et al. Trajectory of viral RNA load among persons with incident SARS-CoV-2 G614 infection (Wuhan strain) in association with COVID-19 symptom onset and severity. JAMA Netw Open 2022;5:e2142796-e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118. Mokhtari T, Hassani F, Ghaffari N. et al. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J Mol Histol 2020;51:613–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119. Zaim S, Chong JH, Sankaranarayanan V. et al. COVID-19 and multiorgan response. Curr Probl Cardiol 2020;45:100618. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120. Li F, Huang Q, Chen J. et al. Apoptotic cells activate the “Phoenix Rising” pathway to promote wound healing and tissue regeneration. Sci Signal 2010;3:ra13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121. Aucamp J, Bronkhorst AJ, Badenhorst CPS. et al. The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev Camb Philos Soc 2018;93:1649–83. [DOI] [PubMed] [Google Scholar]
- 122. Mittra I, Samant U, Sharma S. et al. Cell-free chromatin from dying cancer cells integrate into genomes of bystander healthy cells to induce DNA damage and inflammation. Cell Death Discov 2017;3:17015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123. Shabrish S, Mittra I.. Cytokine storm as a cellular response to dsDNA breaks: a new proposal. Front Immunol 2021;12:622738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124. Andargie TE, Tsuji N, Seifuddin F. et al. Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight 2021;6: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125. Hammond D, Loghavi S.. Clonal haematopoiesis of emerging significance. Pathology 2021;53:300–11. [DOI] [PubMed] [Google Scholar]
- 126. Zekavat SM, Lin S-H, Bick AG. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med 2021;27:1012–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127. Behjati S, Huch M, van Boxtel R. et al. Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature 2014;513:422–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128. Jacobs KB, Yeager M, Zhou W. et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012;44:651–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129. Martincorena I, Roshan A, Gerstung M. et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015;348:880–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130. Costa BA, da Luz KV, Campos SEV. et al. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature. Hematol Transfus Cell Ther 2022;44:26–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131. Jafarzadeh A, Gosain R, Mortazavi SMJ. et al. Review SARS-CoV-2 infection: a possible risk factor for incidence and recurrence of cancers. Int J Hematol Oncol Stem Cell Res 2022;16:117– 27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132. Rahimmanesh I, Shariati L, Dana N. et al. Cancer occurrence as the upcoming complications of COVID-19. Front Mol Biosci 2021;8:813175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133. Kitamura K, Kangawa K, Kawamoto M. et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553–60. [DOI] [PubMed] [Google Scholar]
- 134. Tsuruda T, Kato J, Kuwasako K. et al. Adrenomedullin: continuing to explore cardioprotection. Peptides 2019;111:47–54. [DOI] [PubMed] [Google Scholar]
- 135. Gar C, Thorand B, Herder C. et al. Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: results from the KORA F4 cohort study. PLoS One 2022;17:e0262330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136. Blet A, Deniau B, Geven C. et al. Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats. Intensive Care Med Exp 2019;7:25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137. Deniau B, Takagi K, Asakage A. et al. Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis. Expert Opin Investig Drugs 2021;30:95–102. [DOI] [PubMed] [Google Scholar]
- 138. Asada Y, Hara S, Marutsuka K. et al. Novel distribution of adrenomedullin-immunoreactive cells in human tissues. Histochem Cell Biol 1999;112:185–91. [DOI] [PubMed] [Google Scholar]
- 139. Naderi A, Liu J, Bennett IC.. BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 2010;126:1596–610. [DOI] [PubMed] [Google Scholar]
- 140. Naderi A. Molecular functions of brain expressed X-linked 2 (BEX2) in malignancies. Exp Cell Res 2019;376:221–6. [DOI] [PubMed] [Google Scholar]
- 141. Khomich OA, Kochetkov SN, Bartosch B. et al. Redox biology of respiratory viral infections. Viruses 2018;10:392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142. Gebhard C, Regitz-Zagrosek V, Neuhauser HK. et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11:29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143. Jin JM, Bai P, He W. et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020;8:152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144. Takahashi T, Ellingson MK, Wong P. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588:315–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145. Yamamoto-Shimojima K, Osawa M, Saito MK. et al. Induced pluripotent stem cells established from a female patient with Xq22 deletion confirm that BEX2 escapes from X-chromosome inactivation. Congenit Anom (Kyoto) 2021;61:63–7. [DOI] [PubMed] [Google Scholar]
- 146. Koo JH, Saraswati M, Margolis FL.. Immunolocalization of Bex protein in the mouse brain and olfactory system. J Comp Neurol 2005;487:1–14. [DOI] [PubMed] [Google Scholar]
- 147. Cook D, Brown D, Alexander R. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 2014;13:419–31. [DOI] [PubMed] [Google Scholar]
- 148. Hartl D, de Luca V, Kostikova A. et al. Translational precision medicine: an industry perspective. J Transl Med 2021;19:245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149. Langreth R, Waldholz M.. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 1999;4:426–7. [PubMed] [Google Scholar]
- 150. Bigdelou B, Sepand MR, Najafikhoshnoo S. et al. COVID-19 and preexisting comorbidities: risks, synergies, and clinical outcomes. Front Immunol 2022;13:890517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151. Crisci CD, Ardusso LRF, Mossuz A. et al. A precision medicine approach to SARS-CoV-2 pandemic management. Curr Treat Options Allergy 2020;7:422–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152. DeMerle K, Angus DC, Seymour CW.. Precision medicine for COVID-19: phenotype anarchy or promise realized? JAMA 2021;325:2041–2. [DOI] [PubMed] [Google Scholar]
- 153. El Kantar S, Nehmeh B, Saad P. et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today 2020; Oct25:1822–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154. Charlton CL, Babady E, Ginocchio CC. et al. Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections. Clin Microbiol RevReviews 32: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155. Kuchar E, Miśkiewicz K, Nitsch-Osuch A. et al. Pathophysiology of clinical symptoms in acute viral respiratory tract infections. In: Pokorski M (ed.), Pulmonary Infection. Advances in Experimental Medicine and Biology. Cham: Springer International Publishing, 2015. p. 25-38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156. Petersen E, Koopmans M, Go U. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2020;20:e238–e44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157. Singh A, Singh RS, Sarma P. et al. A comprehensive review of animal models for coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. Virol Sin 2020;35:290–304. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data and code are also available at GitHub (https://github.com/Mark-A-Taylor/Coronavirus_Portal.git/). An interactive portal is available at http://18.222.95.219:8047. Any additional information required to reproduce this work is available from the corresponding authors.







